Drug Resistant Focal Seizures Therapeutics
1. Journavx patent expiration
Treatment: Treatment of moderate to severe acute pain in adults using suzetrigine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11834441 | VERTEX PHARMS INC | Substituted tetrahydrofurans as modulators of sodium channels |
Dec, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 30, 2030 |
Drugs and Companies using SUZETRIGINE ingredient
NCE-1 date: 30 January, 2029
Market Authorisation Date: 30 January, 2025
Dosage: TABLET
More Information on Dosage
JOURNAVX family patents
